Skip to main content
SpringerLink
Log in
Book cover

Adrenal Disorders pp 245–260Cite as

Diagnosis and Management of Primary Aldosteronism

  • Chapter
  • First Online:

  • 1880 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Primary aldosteronism (PA), the most common form of secondary hypertension, can either be surgically cured or treated with targeted pharmacotherapy. If left untreated, PA has associated cardiovascular morbidity and nephrotoxicity. Thus, clinicians should consider PA in all patients with hypertension and perform case detection testing in those who are at high risk for PA. Confirmatory testing is indicated in most patients who have positive case detection testing. The next step is to determine if patients with confirmed PA have disease that can be cured with surgery or if it should be treated medically—this step is guided by CT scan of the adrenal glands and adrenal vein sampling.

This is a preview of subscription content, log in via an institution.

References

  1. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3–17.

    CAS  PubMed  Google Scholar 

  2. Funder JW. Genetics of primary aldosteronism. Front Horm Res. 2014;43:70–8. [Research Support, Non-U.S. Gov’t].

    PubMed  Google Scholar 

  3. Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT. Incidence of primary aldosteronism uncomplicated “essential” hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA. 1968;205(7):497–502.

    Article  CAS  PubMed  Google Scholar 

  4. Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med. 1967;66(6):1079–90.

    Article  CAS  PubMed  Google Scholar 

  5. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE. The incidence rate of pheochromocytoma and Conn’s syndrome in Denmark, 1977-1981. J Hum Hypertens. 1988;2(3):187–9. [Research Support, Non-U.S. Gov’t].

    CAS  PubMed  Google Scholar 

  6. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J. 1976;2(6035):554–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Streeten DH, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med. 1979;67(3):403–13. [Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  8. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc. 1977;52(9):549–5.

    CAS  PubMed  Google Scholar 

  9. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147(7):1289–93. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  10. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol. 2007;66(5):607–18. [Review].

    Article  CAS  Google Scholar 

  11. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.

    Article  CAS  PubMed  Google Scholar 

  12. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  13. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004 Mar;89(3):1045–50.

    Article  CAS  PubMed  Google Scholar 

  14. Piaditis G, Markou A, Papanastasiou L, Androulakis I, Kaltsas G. Progress in primary aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172(5):R191–203.

    Article  CAS  PubMed  Google Scholar 

  15. Ma JT, Wang C, Lam KS, Yeung RT, Chan FL, Boey J, et al. Fifty cases of primary hyperaldosteronism in Hong Kong Chinese with a high frequency of periodic paralysis. Evaluation of techniques for tumour localisation. Q J Med. 1986;61(235):1021–37.

    CAS  PubMed  Google Scholar 

  16. Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin N Am. 1988;17(2):367–95. [Review].

    Google Scholar 

  17. Torres VE, Young WF Jr, Offord KP, Hattery RR. Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med. 1990;322(6):345–51. [Case Reports].

    Article  CAS  PubMed  Google Scholar 

  18. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070–6. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  19. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243–8.

    Article  CAS  PubMed  Google Scholar 

  20. Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014;99(5):1593–8.

    Article  CAS  PubMed  Google Scholar 

  21. Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997;20(2):85–90. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  22. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27(5):1039–45. [Comparative Study Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  23. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141(12):1589–93. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  24. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin N Am. 2002;31(3):619–32. [Review].

    Article  CAS  Google Scholar 

  25. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993;153(18):2125–9. [Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  26. Young WF Jr. Primary aldosteronism: diagnosis. In: Mansoor GA, editor. Secondary hypertension: clinical presentation, diagnosis, and treatment. Totowa: Humana Press; 2004. p. 119–37.

    Chapter  Google Scholar 

  27. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51(2):386–94. [Clinical Trial Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  28. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18(6):805–12. [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  29. Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM. Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension. 2001;37(3):856–61. [Clinical Trial Comparative Study].

    Article  CAS  PubMed  Google Scholar 

  30. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Gifford RW, et al. The changing clinical spectrum of primary aldosteronism. Am J Med. 1983;74(4):641–51. [Comparative Study Research Support, U.S. Gov’t, P.H.S.].

    Article  CAS  PubMed  Google Scholar 

  31. Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab. 2014;99(8):2745–53. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  32. Stowasser M, Gordon RD. Primary aldosteronism—careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217(1–2):33–9. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  33. Thibonnier M, Plouin PF, Menard J, Corvol P. Primary hyperaldosteronism: diagnostic value of the administration of a single dose of captopril. Ann Med Interne (Paris). 1983;134(3):251–5.

    CAS  Google Scholar 

  34. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135(4):258–61.

    Article  CAS  PubMed  Google Scholar 

  35. Citton M, Viel G, Rossi GP, Mantero F, Nitti D, Iacobone M. Outcome of surgical treatment of primary aldosteronism. Langenbeck's Arch Surg. 2015;400(3):325–31.

    Article  Google Scholar 

  36. Wachtel H, Cerullo I, Bartlett EK, Kelz RR, Cohen DL, Karakousis GC, et al. Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism. Surgery. 2014;156(6):1394–403.

    Article  PubMed  Google Scholar 

  37. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–35.

    Article  PubMed  Google Scholar 

  38. Young WF Jr, Hogan MJ. Renin-independent hypermineralocorticoidism. Trends Endocrinol Metab. 1994;5(3):97–106.

    Article  CAS  PubMed  Google Scholar 

  39. Lim V, Guo Q, Grant CS, Thompson GB, Richards ML, Farley DR, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab. 2014;99(8):2712–9. [Observational Study].

    Article  CAS  PubMed  Google Scholar 

  40. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460–84. [Research Support, U.S. Gov’t, P.H.S. Review].

    CAS  PubMed  Google Scholar 

  41. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151(5):329–37. [Review].

    Article  PubMed  Google Scholar 

  42. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol. 2009;70(1):14–7.

    Article  Google Scholar 

  43. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005;25(Suppl 1):S143–58. [Review].

    Article  PubMed  Google Scholar 

  44. Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60. [Consensus Development Conference].

    Article  CAS  PubMed  Google Scholar 

  45. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94(4):1191–7. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94(3):869–75. [Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  47. Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg. 2004;91(10):1259–74. [Review].

    Article  CAS  PubMed  Google Scholar 

  48. Celen O, O’Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg. 1996;131(6):646–50.

    Article  CAS  PubMed  Google Scholar 

  49. Ishidoya S, Ito A, Sakai K, Satoh M, Chiba Y, Sato F, et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol. 2005;174(1):40–3. [Comparative Study].

    Article  PubMed  Google Scholar 

  50. Chiang WF, Cheng CJ, Wu ST, Sun GH, Lin MY, Sung CC, et al. Incidence and factors of post-adrenalectomy hyperkalemia in patients with aldosterone producing adenoma. Clin Chim Acta. 2013;424:114–8.

    Article  CAS  PubMed  Google Scholar 

  51. Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002;89(12):1587–93. [Comparative Study Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

  52. Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med. 1999;131(2):105–8.

    Article  CAS  PubMed  Google Scholar 

  53. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens. 2001;19(3):353–61.

    Article  CAS  PubMed  Google Scholar 

  54. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820–5.

    Article  CAS  PubMed  Google Scholar 

  55. Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–90. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t].

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN, USA

    William F. Young Jr. M.D., M.Sc

Authors
  1. William F. Young Jr. M.D., M.Sc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William F. Young Jr. M.D., M.Sc .

Editor information

Editors and Affiliations

  1. Div of Endocrinology and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA

    Alice C. Levine

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Young, W.F. (2018). Diagnosis and Management of Primary Aldosteronism. In: Levine, A. (eds) Adrenal Disorders. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-62470-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62470-9_11

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-62469-3

  • Online ISBN: 978-3-319-62470-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation